Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
Recruiting · NCT06218875
Conditions: AAA - Abdominal Aortic Aneurysm
At a glance
- Research payments reported, 2025
- $3,523
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 2,000
About the trial
- Sponsor
- W.L.Gore & Associates
- Dates
- Started 2024-05-07; completion 2042-09-30
- Results posted
- Not yet
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.
From ClinicalTrials.gov, last updated 2026-02-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $3,523 in research payments for this study in 2025 (1 payments).
Products named: Product in Development
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Louisville $3,523
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.